Home > Haematology > ASH 2019 > CAR T and Beyond > BCMA-targeted CAR T therapy yields 100% response in relapsed/refractory MM

BCMA-targeted CAR T therapy yields 100% response in relapsed/refractory MM

Presented By
Dr Deepu Madduri, Mount Sinai Medical Center, USA
Conference
ASH 2019
Trial
Phase 1/2, CARTITUDE-1
All 29 patients with progressive myeloma included in the phase 1b/2 CARTITUDE-1 trial attained objective responses with JNJ-4528, including complete responses in two-thirds of the patients [1]. All patients evaluable for minimal residual disease (MRD) were MRD-negative. The study, presented by Dr Deepu Madduri (Mount Sinai Medical Center, USA), examined the investigational CAR T-cell therapy JNJ-4528. These CAR T-cells bind to 2 different epitopes on the B-cell maturation antigen (BCMA). BCMA is almost always overexpressed in multiple myeloma. The study population was heavily pre-treated, had a median age of 60 years, a median disease duration of 6 years, as well as a median of 5 prior lines of therapy. All of the patients had received 3 standard therapies for myeloma (i.e. protease inhibitor, immunomodulatory agent, and CD38 inhibitor), and all but 2 of the...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on